LifeMD beats by $0.03, misses on revs; Issues downside Q4 revenue guidance
Reports Q3 EPS of ($0.11), $0.03 better than the ($0.14) FactSet Consensus estimate; Revenue decreas
Reports Q3 EPS of ($0.11), $0.03 better than the ($0.14) FactSet Consensus estimate; Revenue decreas